Similar articles

• Long-term response to successful acute pharmacological treatment of psychotic depression.

  Wijkstra J, Burger H, van den Broek WW, Birkenhäger TK, Janzing JG, Boks MP, Bruijn JA, van der Loos ML, Breteler LM, Verkes RJ, Nolen WA. Wijkstra J, et al. J Affect Disord. 2010 Jun;123(1-3):238-42. doi: 10.1016/j.jad.2009.10.014. Epub 2009 Oct 31. J Affect Disord. 2010. PMID: 19880189 Clinical Trial.
• Efficacy of imipramine in psychotic versus nonpsychotic depression.

  Birkenhager TK, van den Broek WW, Mulder PG, Moleman P, Bruijn JA. Birkenhager TK, et al. J Clin Psychopharmacol. 2008 Apr;28(2):166-70. doi: 10.1097/JCP.0b013e318166c51c. J Clin Psychopharmacol. 2008. PMID: 18344726
• HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.

  Bech P, Boyer P, Germain JM, Padmanabhan K, Haudiquet V, Pitrosky B, Tourian KA. Bech P, et al. Pharmacopsychiatry. 2010 Nov;43(7):271-6. doi: 10.1055/s-0030-1263173. Epub 2010 Sep 9. Pharmacopsychiatry. 2010. PMID: 20830664
• [Antidepressive agents in the elderly].

  de Hooge JK. de Hooge JK. Tijdschr Gerontol Geriatr. 1990 Dec;21(6):259-67. Tijdschr Gerontol Geriatr. 1990. PMID: 1980385 Review. Dutch.
• Psychopharmacologic treatment of depression.

  Extein I, Gold MS, Pottash AL. Extein I, et al. Psychiatr Clin North Am. 1984 Sep;7(3):503-17. Psychiatr Clin North Am. 1984. PMID: 6148743 Review.